Synopsis
Synopsis
0
VMF
0
FDA Orange Book
0
Canada
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Apo Domperidone
2. Apo-domperidone
3. Domidon
4. Domperidon
5. Domperidon Al
6. Domperidon Hexal
7. Domperidon Stada
8. Domperidon Teva
9. Domperidon-teva
10. Domperidona Gamir
11. Domperidone Maleate
12. Domperidone Maleate (1:1)
13. Domperidone Monohydrochloride
14. Gamir, Domperidona
15. Gastrocure
16. Hexal, Domperidon
17. Maleate, Domperidone
18. Monohydrochloride, Domperidone
19. Motilium
20. Nauzelin
21. Novo Domperidone
22. Novo-domperidone
23. Nu Domperidone
24. Nu-domperidone
25. Pridys
26. Pms Domperidone
27. Pms-domperidone
28. R-33,812
29. R-33812
30. R33,812
31. R33812
32. Ratio Domperidone
33. Ratio-domperidone
34. Stada, Domperidon
1. 57808-66-9
2. Motilium
3. Nauzelin
4. Domperidonum
5. Domperidona
6. C22h24cln5o2
7. R-33812
8. R 33,812
9. 4-(5-chloro-2-oxo-1-benzimidazolinyl)-1-[3-(2-oxobenzimidazolinyl)propyl]piperidine
10. Nsc299589
11. Nsc-299589
12. 5-chloro-1-(1-(3-(2-oxo-1-benzimidazolinyl)propyl)-4-piperidyl)-2-benzimidazolinone
13. Domperidone (motilium)
14. R33812
15. Nsc-759575
16. Kw 5338
17. 6-chloro-3-[1-[3-(2-oxo-3h-benzimidazol-1-yl)propyl]piperidin-4-yl]-1h-benzimidazol-2-one
18. Mls000069343
19. Chembl219916
20. Chebi:31515
21. Nsc 299589
22. 2h-benzimidazol-2-one, 5-chloro-1-(1-(3-(2,3-dihydro-2-oxo-1h-benzimidazol-1-yl)propyl)-4-piperidinyl)-1,3-dihydro-
23. 5-chloro-1-[1-[3-(2,3-dihydro-2-oxo-1h-benzimidazol-1-yl)propyl]-4-piperidinyl]-1,3-dihydro-2h-benzimidazol-2-one
24. 5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-1h-benzimidazol-1-yl)propyl]piperidin-4-yl}-1,3-dihydro-2h-benzimidazol-2-one
25. Motinorm
26. Costi
27. 5-chloro-1-[1-[3-(2-oxo-1-benzimidazolinyl)propyl]-4-piperidyl]-2-benzimidazolinone
28. Dsstox_cid_25116
29. Dsstox_rid_80682
30. Dsstox_gsid_45116
31. 1-(3-(4-(5-chloro-2-oxo-2,3-dihydrobenzo[d]imidazol-1-yl)piperidin-1-yl)propyl)-1h-benzo[d]imidazol-2(3h)-one
32. 5-chloro-1-(1-(3-(2-oxo-2,3-dihydro-1h-benzo[d]imidazol-1-yl)propyl)piperidin-4-yl)-1h-benzo[d]imidazol-2(3h)-one
33. 5-chloro-1-(1-(3-(2-oxo-2,3-dihydrobenzo[d]imidazol-1-yl)propyl)piperidin-4-yl)-1h-benzo[d]imidazol-2(3h)-one
34. 5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-1h-1,3-benzodiazol-1-yl)propyl]piperidin-4-yl}-2,3-dihydro-1h-1,3-benzodiazol-2-one
35. 5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-propyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one
36. Domperidonum [inn-latin]
37. Domperidona [inn-spanish]
38. 5587267z69
39. Motillium
40. Motilium (tn)
41. Smr000326802
42. Cas-57808-66-9
43. Kw-5338
44. Lopac-d-122
45. Sr-01000003002
46. Einecs 260-968-7
47. Brn 0903774
48. Nauzelin Od
49. Domperidone,(s)
50. 5-chloro-1-{1-[3-(2,3-dihydro-2-oxo-1h-benzimidazol-1-yl)propyl]-4-piperidinyl}-1,3-dihydro-2h-benzimidazol-2-one
51. Domperidone [usan:inn:ban:jan]
52. Prestwick_794
53. Mfcd00069256
54. Nci299589
55. Unii-5587267z69
56. Hs-0067
57. Spectrum_000391
58. Opera_id_616
59. Specplus_000825
60. Domperidone [mi]
61. Prestwick0_000461
62. Prestwick1_000461
63. Prestwick2_000461
64. Prestwick3_000461
65. Spectrum4_000087
66. Domperidone [inn]
67. Domperidone [jan]
68. Domperidone [usan]
69. Biomol-nt_000022
70. Domperidone - Pharma Grade
71. Domperidone [vandf]
72. Ncistruc1_001686
73. Ncistruc2_001819
74. Domperidone [mart.]
75. Lopac0_000427
76. Schembl43729
77. Bspbio_002350
78. Domperidone [who-dd]
79. Gtpl965
80. Kbiogr_000354
81. Kbioss_000871
82. 5-24-02-00402 (beilstein Handbook Reference)
83. Mls000859942
84. Mls001306482
85. Mls002222324
86. Divk1c_006921
87. Spectrum2300212
88. Spbio_002501
89. Bpbio1_000620
90. Bpbio1_001185
91. Domperidone [green Book]
92. Dtxsid1045116
93. Domperidone (jp17/usan/inn)
94. Kbio1_001865
95. Kbio2_000871
96. Kbio2_003439
97. Kbio2_006007
98. Domperidone [ep Monograph]
99. Hms1922n04
100. Hms2089c14
101. Hms2093n22
102. Hms2096c21
103. Hms2230n18
104. Hms3261e16
105. Hms3269o13
106. Hms3370l03
107. Hms3413f15
108. Hms3656m21
109. Hms3677f15
110. Hms3713c21
111. Hms3884n19
112. Pharmakon1600-02300212
113. Bcp28265
114. Domperidone 1.0 Mg/ml In Methanol
115. Hy-b0411
116. Zinc4175569
117. Tox21_110056
118. Tox21_500427
119. Bbl028136
120. Bdbm50241107
121. Ccg-37870
122. Ncgc00014670
123. Nsc759575
124. S2461
125. Stk622843
126. Akos005555858
127. Tox21_110056_1
128. Ac-2037
129. Db01184
130. Domperidone, Powder, >=98% (hplc)
131. Lp00427
132. Nsc 759575
133. Sdccgsbi-0050412.p004
134. Ncgc00014670-01
135. Ncgc00014670-02
136. Ncgc00014670-03
137. Ncgc00014670-04
138. Ncgc00014670-05
139. Ncgc00014670-06
140. Ncgc00014670-07
141. Ncgc00014670-08
142. Ncgc00014670-09
143. Ncgc00014670-10
144. Ncgc00014670-11
145. Ncgc00014670-12
146. Ncgc00014670-13
147. Ncgc00014670-14
148. Ncgc00014670-16
149. Ncgc00014670-17
150. Ncgc00014670-28
151. Ncgc00015306-01
152. Ncgc00021472-02
153. Ncgc00021472-03
154. Ncgc00021472-04
155. Ncgc00021472-05
156. Ncgc00021472-06
157. Ncgc00021472-07
158. Ncgc00021472-08
159. Ncgc00097773-01
160. Ncgc00261112-01
161. 2h-benzimidazol-2-one, 1,3-dihydro-5-chloro-1-(1-(3-(2,3-dihydro-2-oxo-1h-benzimidazol-1-yl)propyl)-4-piperidinyl)-
162. 5-chloro-1-(1-(3-(2-oxo-2,3-dihydro-1h-benzimidazol-1-yl)propyl)-4-piperidinyl)-1,3-dihydro-2h-benzimidazol-2-one
163. 5-chloro-1-(1-(3-(2-oxo-2,3-dihydro-1h-benzo[d]imidazol-1-yl)propyl)piperidin-4-yl)-1,3-dihydro-2h-benzo[d]imidazol-2-one
164. Bd164379
165. Nci60_002512
166. Smr000058969
167. Ab00052423
168. D4125
169. Eu-0100427
170. Ft-0625588
171. Sw196931-3
172. C75710
173. D01745
174. Ab00052423-06
175. Ab00052423-07
176. Ab00052423_08
177. Ab00052423_09
178. 808d669
179. A831618
180. L000230
181. Q424238
182. R 33812
183. Sr-01000003002-2
184. Sr-01000003002-4
185. Sr-01000003002-7
186. W-105440
187. Brd-k38305202-001-02-6
188. Brd-k38305202-001-08-3
189. Domperidone, European Pharmacopoeia (ep) Reference Standard
190. 5-chloro-1-[1-[3-(2-oxo-1-benzimidazolyl)propyl]-4-piperidyl]benzimidazol-2-one
191. 1h-benzimidazol-2-ol, 5-chloro-1-[1-[3-(2-hydroxy-1h-benzimidazol-1-yl)propyl]-4-piperidinyl]-
192. 2h-benzimidazol-2-one,3-dihydro-2-oxo-1h-benzimidazol-1-yl)propyl]-4-piperidinyl]-1,3-dihydro-
193. 5-chloro-1-[1-[3-(2,3-dihydro-2-oxo -1h-benzimidazol-1-yl)propyl]-4-piperidinyl]-1,3-d Ihydro-2h-benzimidazol-2-one
194. 5-chloro-1-{1-[3-(1,3-dihydro-2-oxo-2h-benzimidazol-1-yl)propyl]-4-piperidinyl}-1,3-dihydro-2h-benzimidazol-2-one
195. 5-chloro-1-{1-[3-(2-hydroxy-2,3-dihydro-benzoimidazol-1-yl)-propyl]-piperidin-4-yl}-2,3-dihydro-1h-benzoimidazol-2-ol
196. 5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-propyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one(domperidone)
197. 6-chloro-3-[1-[3-(2-oxo-3a,7a-dihydro-3h-benzimidazol-1-yl)propyl]-4-piperidyl]-3a,7a-dihydro-1h-benzimidazol-2-one
198. Domperidone5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-benzoimidazol-1-yl)-propyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one
| Molecular Weight | 425.9 g/mol |
|---|---|
| Molecular Formula | C22H24ClN5O2 |
| XLogP3 | 3.9 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 5 |
| Exact Mass | 425.1618527 g/mol |
| Monoisotopic Mass | 425.1618527 g/mol |
| Topological Polar Surface Area | 67.9 Ų |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 655 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
For management of dyspepsia, heartburn, epigastric pain, nausea, and vomiting.
Domperidone is a specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.
Antiemetics
Drugs used to prevent NAUSEA or VOMITING. (See all compounds classified as Antiemetics.)
Dopamine Antagonists
Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)
A03FA03
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
A - Alimentary tract and metabolism
A03 - Drugs for functional gastrointestinal disorders
A03F - Propulsives
A03FA - Propulsives
A03FA03 - Domperidone
Domperidone has known human metabolites that include 1-Propyl-1,3-dihydro-2H-benzimidazol-2-one, 3-[3-[4-(5-Chloro-2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]propyl]-6-hydroxy-1H-benzimidazol-2-one, and 5-Chloro-1-(piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
7 hours
Domperidone acts as a gastrointestinal emptying (delayed) adjunct and peristaltic stimulant. The gastroprokinetic properties of domperidone are related to its peripheral dopamine receptor blocking properties. Domperidone facilitates gastric emptying and decreases small bowel transit time by increasing esophageal and gastric peristalsis and by lowering esophageal sphincter pressure. Antiemetic: The antiemetic properties of domperidone are related to its dopamine receptor blocking activity at both the chemoreceptor trigger zone and at the gastric level. It has strong affinities for the D2 and D3 dopamine receptors, which are found in the chemoreceptor trigger zone, located just outside the blood brain barrier, which - among others - regulates nausea and vomiting
API SUPPLIERS
HRV Pharma - Market Expansion Leader in Pharmaceuticals.
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Octavius Pharma has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
Tagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.
Date of Issue : 2024-08-16
Valid Till : 2027-02-26
Written Confirmation Number : WC-0494
Address of the Firm :
Delivering Quality APIs, Drug Intermediates, and Specialty Chemicals to Over 50 Countries Across the Globe.
Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 24424
Submission : 2010-12-13
Status : Active
Type : II
Certificate Number : CEP 1997-094 - Rev 10
Issue Date : 2024-12-20
Type : Chemical
Substance Number : 1009
Status : Valid
Registration Number : 227MF10272
Registrant's Address : C-4, Industrial Area, Uppal Khalsa (V), Uppal (M), Medchal-Malkajgiri (Dist.), Hyderabad-500039. Telangana, India.
Initial Date of Registration : 2015-12-01
Latest Date of Registration :
Date of Issue : 2022-06-17
Valid Till : 2025-07-21
Written Confirmation Number : WC-0032n
Address of the Firm :
NDC Package Code : 66326-101
Start Marketing Date : 2020-01-20
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Cheongsol Biotech Co., Ltd.
Registration Date : 2007-12-28
Registration Number : 20071228-79-D-68-02
Manufacturer Name : SRI KRISHNA Pharmaceuticals limited
Manufacturer Address : C-4 industrial area uppal hydrabad-500039
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5402
Submission : 1984-05-17
Status : Inactive
Type : II
Certificate Number : R1-CEP 1996-069 - Rev 10
Issue Date : 2019-10-22
Type : Chemical
Substance Number : 1009
Status : Valid
Registration Number : 218MF10687
Registrant's Address : Turnhoutseweg 30 B-2340 Beerse Belgium
Initial Date of Registration : 2006-08-11
Latest Date of Registration :
Certificate Number : CEP 2020-315 - Rev 02
Issue Date : 2025-12-22
Type : Chemical
Substance Number : 1009
Status : Valid
Registration Number : 304MF10034
Registrant's Address : 78/A, Bengalrao Nagar, Hyderabad-500 038, Telangana State, India.
Initial Date of Registration : 2022-02-10
Latest Date of Registration :
Date of Issue : 2025-08-01
Valid Till : 2028-07-14
Written Confirmation Number : WC-0183
Address of the Firm :
Registrant Name : Daeshin Pharmaceutical Co., Ltd.
Registration Date : 2023-06-22
Registration Number : 20230111-11-B-472-07(1)
Manufacturer Name : Vasudha Pharma Chem Limited
Manufacturer Address : Unit-II, Plot No. 79, Jawaharlal Nehru Pharma City, Thanam(V), Parawada, Visakhapatnam District - 531019 Andhra Pradesh, India
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5402
Submission : 1984-05-17
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 24424
Submission : 2010-12-13
Status : Active
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
Certificate Number : CEP 2004-096 - Rev 05
Status : Valid
Issue Date : 2023-11-14
Type : Chemical
Substance Number : 1009
Certificate Number : R0-CEP 2003-031 - Rev 01
Status : Expired
Issue Date : 2004-10-01
Type : Chemical
Substance Number : 1009
Certificate Number : R0-CEP 1999-129 - Rev 02
Status : Withdrawn by Holder
Issue Date : 2003-07-03
Type : Chemical
Substance Number : 1009
Certificate Number : R1-CEP 1996-069 - Rev 10
Status : Valid
Issue Date : 2019-10-22
Type : Chemical
Substance Number : 1009
Certificate Number : CEP 2022-374 - Rev 01
Status : Valid
Issue Date : 2024-12-20
Type : Chemical
Substance Number : 1009
Certificate Number : CEP 1997-094 - Rev 10
Status : Valid
Issue Date : 2024-12-20
Type : Chemical
Substance Number : 1009
Certificate Number : CEP 2020-315 - Rev 02
Status : Valid
Issue Date : 2025-12-22
Type : Chemical
Substance Number : 1009
Certificate Number : R1-CEP 2007-203 - Rev 04
Status : Valid
Issue Date : 2020-09-03
Type : Chemical
Substance Number : 1009
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
OPENTOP D (pantoprazole Sodium and domperidone) Delayed-Release tablets are indicated for short-term treatment of Erosive Esophagitis Associated with GERD.
Lead Product(s): Pantoprazole Sodium,Domperidone
Therapeutic Area: Gastroenterology Brand Name: Opentop D
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 28, 2024
Lead Product(s) : Pantoprazole Sodium,Domperidone
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Royal Sense Launches Multiple Products in Pharmaceutical Category
Details : OPENTOP D (pantoprazole Sodium and domperidone) Delayed-Release tablets are indicated for short-term treatment of Erosive Esophagitis Associated with GERD.
Product Name : Opentop D
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 28, 2024
Details:
Domperidone is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Gastroesophageal Reflux.
Lead Product(s): Domperidone,Rabeprazole Sodium,Omeprazole
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 04, 2019
Lead Product(s) : Domperidone,Rabeprazole Sodium,Omeprazole
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of GERDOFF Efficacy in Combination With Proton Pump Inhibitor
Details : Domperidone is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Gastroesophageal Reflux.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 04, 2019
Details:
Domperidone is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Dyspepsia.
Lead Product(s): Domperidone,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 06, 2018
Lead Product(s) : Domperidone,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Domperidone is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Dyspepsia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 06, 2018
Details:
Lansoprazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Gastroesophageal Reflux.
Lead Product(s): Lansoprazole,Domperidone
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 28, 2017
Lead Product(s) : Lansoprazole,Domperidone
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Cardiac Safety of Lansoprazole and Domperidon Combination
Details : Lansoprazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Gastroesophageal Reflux.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 28, 2017
Details:
Lansoprazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Gastroesophageal Reflux.
Lead Product(s): Lansoprazole,Domperidone
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 08, 2016
Lead Product(s) : Lansoprazole,Domperidone
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lansoprazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Gastroesophageal Reflux.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 08, 2016
Details:
Domperidone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Domperidone,Moxifloxacin
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 29, 2016
Lead Product(s) : Domperidone,Moxifloxacin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Domperidone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 29, 2016
Details:
Domperidone is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Gastroenteritis.
Lead Product(s): Domperidone,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 04, 2016
Lead Product(s) : Domperidone,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Domperidone is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Gastroenteritis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 04, 2016
Details:
Domperidone is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Multiple Sclerosis, Relapsing-Remitting.
Lead Product(s): Domperidone,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Alberta Innovates Health Solutions
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 09, 2015
Lead Product(s) : Domperidone,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Alberta Innovates Health Solutions
Deal Size : Inapplicable
Deal Type : Inapplicable
Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS)
Details : Domperidone is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Multiple Sclerosis, Relapsing-Remitting.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 09, 2015
Details:
Domperidone is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Multiple Sclerosis, Chronic Progressive.
Lead Product(s): Domperidone,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Alberta Innovates Health Solutions
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 04, 2014
Lead Product(s) : Domperidone,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Alberta Innovates Health Solutions
Deal Size : Inapplicable
Deal Type : Inapplicable
Domperidone in Secondary Progressive Multiple Sclerosis (SPMS)
Details : Domperidone is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Multiple Sclerosis, Chronic Progressive.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 04, 2014
Details:
Pantoprazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Gastroesophageal Reflux.
Lead Product(s): Pantoprazole Sodium,Domperidone
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 19, 2012
Lead Product(s) : Pantoprazole Sodium,Domperidone
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pantoprazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Gastroesophageal Reflux.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 19, 2012
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
32
PharmaCompass offers a list of Domperidone API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Domperidone manufacturer or Domperidone supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Domperidone manufacturer or Domperidone supplier.
PharmaCompass also assists you with knowing the Domperidone API Price utilized in the formulation of products. Domperidone API Price is not always fixed or binding as the Domperidone Price is obtained through a variety of data sources. The Domperidone Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Domperidone manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Domperidone, including repackagers and relabelers. The FDA regulates Domperidone manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Domperidone API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Domperidone manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Domperidone supplier is an individual or a company that provides Domperidone active pharmaceutical ingredient (API) or Domperidone finished formulations upon request. The Domperidone suppliers may include Domperidone API manufacturers, exporters, distributors and traders.
click here to find a list of Domperidone suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Domperidone DMF (Drug Master File) is a document detailing the whole manufacturing process of Domperidone active pharmaceutical ingredient (API) in detail. Different forms of Domperidone DMFs exist exist since differing nations have different regulations, such as Domperidone USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Domperidone DMF submitted to regulatory agencies in the US is known as a USDMF. Domperidone USDMF includes data on Domperidone's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Domperidone USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Domperidone suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Domperidone Drug Master File in Japan (Domperidone JDMF) empowers Domperidone API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Domperidone JDMF during the approval evaluation for pharmaceutical products. At the time of Domperidone JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Domperidone suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Domperidone Drug Master File in Korea (Domperidone KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Domperidone. The MFDS reviews the Domperidone KDMF as part of the drug registration process and uses the information provided in the Domperidone KDMF to evaluate the safety and efficacy of the drug.
After submitting a Domperidone KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Domperidone API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Domperidone suppliers with KDMF on PharmaCompass.
A Domperidone CEP of the European Pharmacopoeia monograph is often referred to as a Domperidone Certificate of Suitability (COS). The purpose of a Domperidone CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Domperidone EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Domperidone to their clients by showing that a Domperidone CEP has been issued for it. The manufacturer submits a Domperidone CEP (COS) as part of the market authorization procedure, and it takes on the role of a Domperidone CEP holder for the record. Additionally, the data presented in the Domperidone CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Domperidone DMF.
A Domperidone CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Domperidone CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Domperidone suppliers with CEP (COS) on PharmaCompass.
A Domperidone written confirmation (Domperidone WC) is an official document issued by a regulatory agency to a Domperidone manufacturer, verifying that the manufacturing facility of a Domperidone active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Domperidone APIs or Domperidone finished pharmaceutical products to another nation, regulatory agencies frequently require a Domperidone WC (written confirmation) as part of the regulatory process.
click here to find a list of Domperidone suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Domperidone as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Domperidone API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Domperidone as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Domperidone and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Domperidone NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Domperidone suppliers with NDC on PharmaCompass.
Domperidone Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Domperidone GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Domperidone GMP manufacturer or Domperidone GMP API supplier for your needs.
A Domperidone CoA (Certificate of Analysis) is a formal document that attests to Domperidone's compliance with Domperidone specifications and serves as a tool for batch-level quality control.
Domperidone CoA mostly includes findings from lab analyses of a specific batch. For each Domperidone CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Domperidone may be tested according to a variety of international standards, such as European Pharmacopoeia (Domperidone EP), Domperidone JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Domperidone USP).
